Business Context and Reporting Period
This Form 8-K is filed by Blackboxstocks Inc. (trading symbol: BLBX) on January 13, 2025. The filing addresses two separate instances of non-compliance with Nasdaq listing standards. The registrant is an emerging growth company incorporated in Nevada.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and listing compliance matters.
Material Changes and Compliance Issues
- Annual Meeting Non-Compliance (Rule 5620): The Company failed to hold its 2024 annual meeting of stockholders by December 31, 2024. Nasdaq issued a notice on January 13, 2025, granting 45 calendar days (until February 27, 2025) to submit a compliance plan. If accepted, the Company may receive an extension up to June 30, 2025.
- Board Independence Non-Compliance (Rule 5605): Due to the passing of director Ray Balestri, the Company no longer meets the requirement for a majority of independent directors or an Audit Committee comprised of at least three independent directors.
- Cure Period for Board Composition: Nasdaq granted a cure period ending on the earlier of the next annual meeting or January 4, 2026. If the next annual meeting occurs before July 3, 2025, the deadline is July 3, 2025.
Outlook, Management Commentary, and Risks
Management Action Plan: The Company has scheduled its 2024 annual meeting for February 7, 2025, to cure the annual meeting non-compliance and intends to submit its plan to Nasdaq by that date. Regarding board composition, management is currently reviewing and evaluating options to regain compliance within the provided cure period.
Risks: Failure to regain compliance with Nasdaq listing rules within the specified cure periods could result in the delisting of the Company's common stock from the Nasdaq Capital Market.
Investor Verification Checklist
- Confirm the successful holding of the 2024 annual meeting on February 7, 2025.
- Monitor the Company's submission of a compliance plan to Nasdaq by February 27, 2025.
- Verify the appointment of new independent directors to satisfy Rule 5605 requirements before the applicable cure deadline.
- Check for any subsequent Nasdaq communications regarding the acceptance of the compliance plan or potential delisting notices.